VentriPoint Diagnostics (VPT) Q3 2025 earnings summary

Executive summary

• Focused on commercializing VMS+ cardiac diagnostic platform, with direct sales in North America and hybrid models in Europe and the UK.

• Achieved regulatory milestones: FDA 510(k) clearance, EU CE-Mark, and Health Canada approval for VMS+ V4.0.

• Expanded commercial operations, upgraded customer sites, and signed key collaboration agreements.

• Installed new systems and upgraded existing ones, with a growing installed base in the US, Europe, and UK.

Financial highlights

• Revenue for Q3 2025 was $104,304, up from $64,507 in Q3 2024; nine-month revenue was $175,624, up from $95,172 year-over-year.

• Net loss for Q3 2025 was $752,084, improved from $1,251,079 in Q3 2024; nine-month net loss was $3,000,491, improved from $3,859,958 year-over-year.

• Operating expenses for Q3 2025 were $750,263, down from $1,258,517 in Q3 2024; nine-month operating expenses were $2,836,523, down from $3,845,524 year-over-year.

• Cash used in operating activities for nine months was $955,549, down from $2,665,385 year-over-year.

• Cash provided by financing activities was $944,081 for nine months, down from $1,492,958 year-over-year.

• Cash and cash equivalents at September 30, 2025, were $68,322.

Outlook and guidance

• Plans to raise approximately $500,000 by year-end 2025 to support ongoing operations.

• Management confident in ability to secure additional capital with continued support from advisors, shareholders, and improving equity markets.

• Focus remains on scaling commercial operations and expanding market presence.